Human Papilloma Virus (HPV)
17
5
5
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
12%
2 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (17)
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
HPV Testing as a Prevention of Cervical Dysplasia and Cancer Before Planned Subtotal Hysterectomy
Effectiveness of a Vaginal Gel on CIN1/2 Regression and HPV Clearance.
Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Combination Therapy for Warts: Candida Antigen vs. Topical Keratolytic
Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts
Knowledge and Beliefs of Hearing Impaired Individuals Regarding Human Papillomavirus (HPV)
Impact of HPV Education on Knowledge, Awareness, and Concern
Transmission of Oncogenic HPV Infection Among Families
Human Papilloma Virus Awareness Intervention
Peer Education on HPV: Impact on Health Sciences Students' Knowledge, Awareness, and Concern
Unidos Contra el VPH
Usability of HPV Vaccine Reminders
Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients